TP53 and acute myeloid leukemia: For brevity, this section will only review the newly included entities and omit the specifically enumerated bone marrow failure syndromes, updated terminology and subtyping of juvenile myelomonocytic leukemia (JMML)-associated syndromes, and germline TP53 alterations, the latter of which were briefly mentioned in the AML-RGA section above.